{"entity":{"id":"progression","kind":"term","name":"Progression","aka":["progressive disease","disease progression","progressed","progresses","progressing","on progression","at progression","after progression","post-progression","radiographic progression","progressed on","growth of the tumour","tumour growth","tumor growth"],"tldr":"The cancer is growing or spreading despite treatment, or after it. Progression usually means the current drug has stopped working and it is time to switch to the next line.","summary":"RECIST defines progression as at least a 20% increase in the sum of target-lesion diameters (and at least 5 mm absolute), or the appearance of any new lesion; clinical progression (worsening symptoms) can also count. Progression triggers the move from first-line to second-line therapy and, increasingly, a repeat biopsy or liquid biopsy to see what resistance mechanism has emerged. Time to progression is the basis of progression-free survival, the commonest primary endpoint in trials, and 'pseudoprogression', an apparent enlargement caused by immune cells flooding a tumour, can mislead early scans during immunotherapy.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Progressive_disease","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Progressive_disease"}],"tags":[],"related":["pfs","recist","first-line","resistance","relapse-recurrence","stable-disease","partial-response"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Clinic basics"},"route":"/terms/progression/","neighbours":{"term":[{"id":"complete-response","kind":"term","name":"Complete response","route":"/terms/complete-response/"},{"id":"resistance","kind":"term","name":"Drug resistance (primary and acquired)","route":"/terms/resistance/"},{"id":"first-line","kind":"term","name":"Lines of therapy","route":"/terms/first-line/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"partial-response","kind":"term","name":"Partial response","route":"/terms/partial-response/"},{"id":"pfs","kind":"term","name":"Progression-free survival (PFS)","route":"/terms/pfs/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"},{"id":"relapse-recurrence","kind":"term","name":"Recurrence and relapse","route":"/terms/relapse-recurrence/"},{"id":"refractory","kind":"term","name":"Refractory","route":"/terms/refractory/"},{"id":"remission","kind":"term","name":"Remission","route":"/terms/remission/"},{"id":"stable-disease","kind":"term","name":"Stable disease","route":"/terms/stable-disease/"},{"id":"tumour-marker","kind":"term","name":"Tumour marker","route":"/terms/tumour-marker/"}],"journal":[{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","route":"/journals/pathology-and-oncology-research/"}]}}